Nirsevimab (Beyfortus): the RSV shot for infants

Beyfortus is arguably the most significant advance in infant respiratory health in decades. But parents often run into a confusing detail: it's not a vaccine. Understanding what it is — and how it works differently — helps you understand why timing matters and what to expect.

What is Beyfortus?

Beyfortus (generic name: nirsevimab) is a monoclonal antibody. It doesn't train your baby's immune system — it directly delivers pre-made antibodies that neutralize RSV. Think of it as a head start: instead of waiting for the immune system to generate its own protection, you're handing the baby a ready-made shield.

Because it provides passive immunity (borrowed antibodies rather than actively trained immune cells), it doesn't produce long-lasting immunity the way a vaccine does. The antibodies protect for roughly 5–6 months — covering the typical RSV season — and then naturally clear from the body.

Who is it for?

Per CDC recommendations (as of 2025–26):

• All infants under 8 months entering their first RSV season — universally recommended
• Children 8–19 months who are at heightened risk for severe RSV, including those with: chronic lung disease of prematurity, hemodynamically significant congenital heart disease, severe immunocompromise, cystic fibrosis with severe disease, certain other high-risk conditions

Children born during RSV season (roughly October–March) are typically given Beyfortus shortly after birth, before leaving the hospital or at the first pediatric visit. Children born before RSV season should receive it in the fall.

When should it be given?

Timing depends on when your baby was born relative to the RSV season:

• Born during RSV season (October–March): Give as soon as possible after birth, ideally before hospital discharge
• Born before RSV season (spring/summer): Give in September–October before the season begins
• Premature infants: May receive it in the NICU before discharge if RSV season is active

The window that matters most: it should be given before the baby's first significant RSV exposure, not after. Once a baby has RSV, Beyfortus won't help for that infection.

What about palivizumab (Synagis)?

Palivizumab (brand name Synagis) is an older monoclonal antibody that has been used for decades to protect high-risk premature infants from RSV. It requires monthly injections throughout RSV season (typically 5 doses). Beyfortus has largely replaced palivizumab for most infants because a single dose covers the whole season — but palivizumab remains an option for some high-risk groups and in access situations. Ask your pediatrician which is appropriate for your situation.

Availability and insurance

Beyfortus is covered under the Vaccines for Children (VFC) program for eligible children, and most private insurance plans cover it. However, supply has been constrained in some areas during peak demand. If your baby is eligible, ask your pediatrician about it before September — practices that order in advance are more likely to have it available when you need it.

What to expect after the injection

Beyfortus is given as a single intramuscular injection, typically in the thigh. Side effects are generally mild:

• Injection site redness, swelling, or tenderness
• Mild fussiness for a day or two
• Rarely: mild fever

Severe reactions are rare. Your pediatrician's office will typically ask you to stay for 15–20 minutes after the injection to monitor.

Does it mean my baby can't get RSV?

No — Beyfortus significantly reduces the risk of severe RSV illness and hospitalization, but it does not completely prevent infection. In clinical trials, it reduced RSV-associated lower respiratory tract infections by about 75–80% and RSV hospitalizations by about 80%. Your baby could still get mild RSV symptoms. The goal is to prevent the severe, dangerous form of the illness.

Not medical advice. Eligibility and timing should be confirmed with your pediatrician. Guidelines may have been updated since this page was written.